Literature DB >> 32606043

Quantitative analysis of pulmonary vasculature in systemic sclerosis at spirometry-gated chest CT.

Mariaelena Occhipinti1, Cosimo Bruni2,3, Gianna Camiciottoli4,5, Maurizio Bartolucci6, Silvia Bellando-Randone2,3, Anna Bassetto3, Giovanna Cuomo7, Dilia Giuggioli8, Giulia Ciardi5, Alessio Fabbrizzi5, Sara Tomassetti3,5, Federico Lavorini3,5, Massimo Pistolesi3, Stefano Colagrande4,9, Marco Matucci-Cerinic3,10.   

Abstract

OBJECTIVE: To prospectively investigate whether differences in pulmonary vasculature exist in systemic sclerosis (SSc) and how they are distributed in patients with different pulmonary function.
METHODS: Seventy-four patients with SSc undergoing chest CT scan for interstitial lung disease (ILD) screening or follow-up were prospectively enrolled. A thorough clinical, laboratory and functional evaluation was performed the same day. Chest CT was spirometry gated at total lung capacity and images were analysed by two automated software programs to quantify emphysema, ILD patterns (ground-glass, reticular, honeycombing), and pulmonary vascular volume (PVV). Patients were divided in restricted (FVC% <80, DLco%<80), isolated DLco% reduction (iDLco- FVC%≥80, DLco%<80) and normals (FVC%≥80, DLco%≥80). Spearman ρ, Mann-Whitney tests and logistic regressions were used to assess for correlations, differences among groups and relationships between continuous variables.
RESULTS: Absolute and lung volume normalised PVV (PVV/LV) correlated inversely with functional parameters and positively with all ILD patterns (ρ=0.75 with ground glass, ρ=0.68 with reticular). PVV/LV was the only predictor of DLco at multivariate analysis (p=0.007). Meanwhile, the reticular pattern prevailed in peripheral regions and lower lung thirds, PVV/LV prevailed in central regions and middle lung thirds. iDLco group had a significantly higher PVV/LV (2.2%) than normal (1.6%), but lower than restricted ones (3.8%).
CONCLUSIONS: Chest CT in SSc detects a progressive increase in PVV/LV as DLco decreases. Redistribution of perfusion to less affected lung regions rather than angiogenesis nearby fibrotic lung may explain the results. Further studies to ascertain whether the increase in PVV/LV reflects a real increase in blood volume are needed. © Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  arterial hypertension; cardiovascular disease; disease activity; pulmonary fibrosis; systemic sclerosis

Mesh:

Year:  2020        PMID: 32606043     DOI: 10.1136/annrheumdis-2020-217359

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  4 in total

Review 1.  The Relationship between Pulmonary Damage and Peripheral Vascular Manifestations in Systemic Sclerosis Patients.

Authors:  Barbara Ruaro; Marco Confalonieri; Francesco Salton; Barbara Wade; Elisa Baratella; Pietro Geri; Paola Confalonieri; Metka Kodric; Marco Biolo; Cosimo Bruni
Journal:  Pharmaceuticals (Basel)       Date:  2021-04-23

2.  Lung Ultrasound B-Lines in the Evaluation of the Extent of Interstitial Lung Disease in Systemic Sclerosis.

Authors:  Cosimo Bruni; Lavinia Mattolini; Lorenzo Tofani; Luna Gargani; Nicholas Landini; Nicola Roma; Gemma Lepri; Martina Orlandi; Serena Guiducci; Silvia Bellando-Randone; Chiara Romei; Yukai Wang; Marco Matucci-Cerinic
Journal:  Diagnostics (Basel)       Date:  2022-07-12

Review 3.  High-Resolution Computed Tomography and Lung Ultrasound in Patients with Systemic Sclerosis: Which One to Choose?

Authors:  Barbara Ruaro; Elisa Baratella; Paola Confalonieri; Marco Confalonieri; Fabio Giuseppe Vassallo; Barbara Wade; Pietro Geri; Riccardo Pozzan; Gaetano Caforio; Cristina Marrocchio; Maria Assunta Cova; Francesco Salton
Journal:  Diagnostics (Basel)       Date:  2021-12-07

Review 4.  Early Diagnosis and Real-Time Monitoring of Regional Lung Function Changes to Prevent Chronic Obstructive Pulmonary Disease Progression to Severe Emphysema.

Authors:  Tony Jung; Neeraj Vij
Journal:  J Clin Med       Date:  2021-12-12       Impact factor: 4.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.